Role of methylmalonic acid and homocysteine in cognitive risk assessment2 min read

Methylmalonic acid (MMA) and homocysteine are important metabolic biomarkers in cognitive risk assessment, particularly in relation to vitamin B12 status and brain health:

Methylmalonic Acid (MMA)

• MMA is a sensitive marker of vitamin B12 deficiency. Elevated MMA levels indicate insufficient B12 activity at a cellular level.
• High serum MMA levels are independently associated with poorer cognitive performance and accelerated cognitive decline, even when vitamin B12 levels appear normal.
• MMA accumulation can contribute directly to neurological damage and is correlated with lower global cognition and episodic memory.
• Studies show a dose-dependent decline in cognitive scores with increasing MMA concentrations above about 170 nmol/L.
• MMA may not be an independent risk factor alone but often serves as a surrogate marker linked to other factors affecting cognition.sciencedirect+4

Homocysteine

• Elevated plasma homocysteine (tHcy) is a strong, modifiable risk factor for cognitive impairment, vascular dementia, and Alzheimer’s disease.
• High homocysteine levels correlate with cognitive decline, white matter brain damage, brain atrophy, and neurofibrillary tangles.
• Mechanistically, homocysteine induces cerebrovascular damage and inflammation, promoting microhemorrhages and cognitive deficits.
• Hyperhomocysteinemia typically defined as >15 µmol/L, is linked to impairments in memory, language, executive function, and overall cognition.
• Clinical trials suggest lowering homocysteine with B vitamins may slow cognitive decline in at-risk populations.frontiersin+4

Summary

• Elevated MMA signals functional B12 deficiency and is associated with worse cognitive outcomes.
• Elevated homocysteine contributes to vascular and inflammatory brain damage, increasing dementia risk.
• Both biomarkers add important information beyond serum B12 and are useful for early detection of cognitive impairment risk, guiding potential nutritional interventions.annualreviews+2

This combined assessment can improve precision in identifying those at higher risk of cognitive decline and dementia due to nutrient-related metabolic dysfunction.

1. https://www.sciencedirect.com/science/article/abs/pii/S1064748125004233
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9276928/
3. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1594103/full
4. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.1090958/full
5. https://www.sciencedirect.com/science/article/pii/S0002916523292047
6. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2018.00350/full
7. https://www.annualreviews.org/doi/10.1146/annurev-nutr-071715-050947
8. https://www.nature.com/articles/s41598-024-69818-1
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3522456/
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC5836397/
11. https://www.nature.com/articles/s41398-024-03015-6
12. https://www.sciencedirect.com/science/article/pii/S266645932500040X
13. https://www.sciencedirect.com/science/article/pii/S0197018624000901
14. https://www.sciencedirect.com/science/article/abs/pii/S0167494323002546
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC1395322/
16. https://www.neurology.org/doi/10.1212/01.WNL.0000032494.05619.93
17. https://www.sciencedirect.com/science/article/pii/S0531556522003540